Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

BRIAN A COSTELL

Allopathic & Osteopathic Physicians Psychiatry & Neurology Epilepsy

NPI
1174563688
CMS profile
766906
Location
BOCA RATON, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$71,569.58

385 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

By paying entity

PY2024 · entire year · sorted by reported total

Paying entityAmountRecords
Eisai Inc. $39,628.09 80
ABBVIE INC. $24,752.75 41
ARGENX US, INC. $1,948.07 8
UCB, Inc. $486.99 18
Novartis Pharmaceuticals Corporation $390.12 32
Merz Pharmaceuticals, LLC $325.51 9
Alexion Pharmaceuticals, Inc. $300.66 13
Lilly USA, LLC $282.53 13
PFIZER INC. $282.31 12
Amgen Inc. $282.18 12
SCILEX PHARMACEUTICALS INC. $264.05 21
ANI Pharmaceuticals, Inc. $245.75 12
Teva Pharmaceuticals USA, Inc. $205.67 11
Takeda Pharmaceuticals U.S.A., Inc. $168.28 5
Genentech USA, Inc. $141.62 6
Amneal Pharmaceuticals LLC $140.84 18
Lundbeck LLC $136.40 5
Biogen, Inc. $136.01 7
Neurocrine Biosciences, Inc. $135.11 7
MDD US Operations, LLC $116.24 4
Alnylam Pharmaceuticals Inc. $108.29 6
CSL Behring $106.43 4
Neurelis, Inc. $106.23 5
Octapharma USA, Inc. $98.57 2
MITSUBISHI TANABE PHARMA AMERICA, INC. $95.23 4
Abbott Laboratories $75.36 3
EMD Serono, Inc. $70.72 3
Celgene Corporation $61.53 3
JAZZ PHARMACEUTICALS INC. $59.65 2
Otsuka America Pharmaceutical, Inc. $57.77 2
ACADIA Pharmaceuticals Inc $42.84 2
InSightec,Inc $33.33 1
CATALYST PHARMACEUTICALS, INC. $32.52 1
SK Life Science, Inc. $30.76 1
Acorda Therapeutics, Inc $28.69 2
Mallinckrodt Hospital Products Inc. $27.92 1
Mylan Specialty L.P. $23.86 1
Kyowa Kirin, Inc. $20.70 1
LivaNova USA, Inc. $20.57 1
Medtronic, Inc. $19.77 1
SpringWorks Therapeutics, Inc. $17.79 1
GENZYME CORPORATION $17.07 1
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $15.79 1
Boston Scientific Corporation $15.68 1
Vanda Pharmaceuticals Inc. $13.33 1

Page 2 of 8; records 51–100 of 385 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

BRIAN A COSTELL

NPI 1174563688 · CMS profile ID 766906

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Epilepsy

BOCA RATON, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 8; records 51–100 of 385 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1174563688?year=2024&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
BRIAN A COSTELL, NPI 1174563688, CMS profile ID 766906. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 8; records 51–100 of 385 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1174563688?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). BRIAN A COSTELL, NPI 1174563688, CMS profile ID 766906. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 8; records 51–100 of 385 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1174563688?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
BRIAN A COSTELL, NPI 1174563688, CMS profile ID 766906, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 8; records 51–100 of 385 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1174563688?year=2024&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

385 matching records · $71,569.58 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 385 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 385.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
SCILEX PHARMACEUTICALS INC. $13.9011/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136284128 CMS
Alexion Pharmaceuticals, Inc. $29.2311/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1093884665 CMS
ABBVIE INC. $29.3411/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103506098 CMS
Amneal Pharmaceuticals LLC $14.3211/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139183058 CMS
ANI Pharmaceuticals, Inc. $21.5411/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1091152956 CMS
ABBVIE INC. $4,200.0011/05/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103146347 CMS
UCB, Inc. $34.7411/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143165352 CMS
Alnylam Pharmaceuticals Inc. $18.8011/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1125834441 CMS
ANI Pharmaceuticals, Inc. $34.7810/31/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1091146726 CMS
ABBVIE INC. $33.3010/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103506096 CMS
Amgen Inc. $27.3510/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1111555003 CMS
ABBVIE INC. $25.0410/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103506094 CMS
Merz Pharmaceuticals, LLC $15.1710/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137947292 CMS
UCB, Inc. $44.5710/28/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143165350 CMS
Medtronic, Inc. $19.7710/24/2024 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1247151764 CMS
Amneal Pharmaceuticals LLC $1.7210/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139183056 CMS
Novartis Pharmaceuticals Corporation $5.9010/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086616771 CMS
Novartis Pharmaceuticals Corporation $6.9310/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086616773 CMS
SCILEX PHARMACEUTICALS INC. $11.4310/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136278482 CMS
Lundbeck LLC $26.6810/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145907297 CMS
Lilly USA, LLC $26.2310/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136078599 CMS
Teva Pharmaceuticals USA, Inc. $9.8210/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1151498869 CMS
ANI Pharmaceuticals, Inc. $22.0510/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1091152208 CMS
ABBVIE INC. $24.9410/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103506092 CMS
Eisai Inc. $912.5010/10/2024 Compensation for serving as faculty or as a speaker for a medical education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110734563 CMS
Eisai Inc. $365.0010/10/2024 Compensation for serving as faculty or as a speaker for a medical education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110734567 CMS
Eisai Inc. $121.8210/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110734589 CMS
ARGENX US, INC. $28.6610/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1142119295 CMS
Alexion Pharmaceuticals, Inc. $18.8810/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1094049515 CMS
MDD US Operations, LLC $15.4210/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1147749692 CMS
Novartis Pharmaceuticals Corporation $13.1710/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086616767 CMS
Novartis Pharmaceuticals Corporation $2.2510/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086616769 CMS
SCILEX PHARMACEUTICALS INC. $5.7510/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136275336 CMS
SK Life Science, Inc. $30.7610/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1154129705 CMS
Neurelis, Inc. $21.9910/03/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145638791 CMS
Amneal Pharmaceuticals LLC $12.7310/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139183052 CMS
Amneal Pharmaceuticals LLC $4.0610/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139183054 CMS
PFIZER INC. $29.2810/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131998809 CMS
Merz Pharmaceuticals, LLC $24.6809/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137947306 CMS
Lundbeck LLC $29.4009/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145907295 CMS
UCB, Inc. $42.5409/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143165348 CMS
ABBVIE INC. $22.5209/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103506090 CMS
Amneal Pharmaceuticals LLC $9.7509/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139183050 CMS
Takeda Pharmaceuticals U.S.A., Inc. $34.5909/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137519746 CMS
SCILEX PHARMACEUTICALS INC. $18.9809/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136271988 CMS
Biogen, Inc. $14.6709/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104846398 CMS
Alnylam Pharmaceuticals Inc. $24.2009/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1125834425 CMS
Teva Pharmaceuticals USA, Inc. $16.9209/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1151498853 CMS
ABBVIE INC. $15.4609/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103506088 CMS
JAZZ PHARMACEUTICALS INC. $25.1709/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1150202876 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $76,898.95 339
PY2020 $86,809.51 379
PY2021 $107,770.70 419
PY2022 $33,902.21 342
PY2023 $31,272.41 277
PY2024 $71,569.58 385
PY2025 $60,697.69 364

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $857,870.90 51
PY2024 Principal investigator $731,660.39 67
PY2023 Recipient $43,517.60 10
PY2023 Principal investigator $574,879.61 46
PY2022 Recipient $6,643.00 3
PY2022 Principal investigator $768,996.83 30
PY2021 Recipient $7,591.95 2
PY2021 Principal investigator $209,112.46 23
PY2020 Recipient $6,463.00 1
PY2020 Principal investigator $218,655.09 25
PY2019 Recipient $40,339.01 5
PY2019 Principal investigator $136,491.05 27

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

51 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $811.92 12/31/2025 Non-covered Recipient Entity
PHYSICIANS GROUP SERVICES PA
A Phase 2 Multicenter, Randomized, Double-blind, Placebo-controlled Study of BOTOX (Botulinum Toxin Type A) Purified Neurotoxin Complex for the Treatment of Upper Limb Essential Tremor No dispute reported 06/30/2026 1202534343
Principal investigator 1 ABBVIE INC. $600.00 12/31/2025 Non-covered Recipient Entity
FIRST CHOICE NEUROLOGY
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Ubrogepant for the Preventive Treatment of Menstrual Migraine with an Open-Label Extension No dispute reported 06/30/2026 1202534345
Principal investigator 1 ABBVIE INC. $1,854.00 12/31/2025 Non-covered Recipient Entity
FIRST CHOICE NEUROLOGY
A Phase 3 Multicenter 24-Week Open-Label Study to Evaluate the Safety, Tolerability, and Efficacy of Atogepant When Added to OnabotulinumtoxinA (BOTOX) for the Preventive Treatment of Chronic Migraine No dispute reported 06/30/2026 1202534347
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $152,506.25 12/24/2025 Non-covered Recipient Entity
Neurology Offices Of South Florida PLLC
Safety/Tolerability of Xanomeline/Trospium (X/T) on Cognition in Participants with Alzheimers Disease No dispute reported 06/30/2026 1235995421
Principal investigator 1 Ipsen Innovation $2,000.00 12/12/2025 Non-covered Recipient Entity
Neurology Offices South Florida
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184288686
Principal investigator 1 Ipsen Innovation $3,000.00 12/12/2025 Non-covered Recipient Entity
Neurology Offices South Florida
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184288688
Principal investigator 1 Ipsen Innovation $1,000.00 12/12/2025 Non-covered Recipient Entity
Neurology Offices South Florida
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184288690
Principal investigator 1 Ipsen Innovation $10,000.00 12/12/2025 Non-covered Recipient Entity
Neurology Offices South Florida
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184288692
Principal investigator 1 Ipsen Innovation $1,000.00 12/12/2025 Non-covered Recipient Entity
Neurology Offices South Florida
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184288694
Principal investigator 1 Ipsen Innovation $3,000.00 12/12/2025 Non-covered Recipient Entity
Neurology Offices South Florida
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184288696
Principal investigator 1 Ipsen Innovation $1,000.00 12/12/2025 Non-covered Recipient Entity
Neurology Offices South Florida
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184288698
Principal investigator 1 ABBVIE INC. $10,126.35 12/04/2025 Non-covered Recipient Entity
NEUROLOGY OFFICES OF S FL PLLC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202527818
Principal investigator 1 ARGENX US, INC. $1,500.00 11/18/2025 Non-covered Recipient Entity
NEUROLOGY OFFICES OF SOUTH FLORIDA
A randomized, double-blinded, placebo-controlled, phase 3, parallel group design study evaluating the efficacy and safety of efgartigimod IV in adult participants with acetylcholine receptor binding antibody (AChR-Ab) seronegative generalized myasthenia gravis (gMG). No dispute reported 06/30/2026 1237154510
Principal investigator 1 ABBVIE INC. $7,357.50 11/05/2025 Non-covered Recipient Entity
NEUROLOGY OFFICES OF S FL PLLC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202522433
Principal investigator 1 PFIZER INC. $17,775.67 10/23/2025 Non-covered Recipient Entity
NEUROLOGY OFFICES OF SOUTH FLORIDA PLLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RIMEGEPANT IN EPISODIC MIGRAINE PREVENTION WITH MULTIPLE DOSING REGIMENS No dispute reported 06/30/2026 1228737884
Principal investigator 1 ABBVIE INC. $29,948.40 10/09/2025 Non-covered Recipient Entity
NEUROLOGY OFFICES OF S FL PLLC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202514757
Principal investigator 1 Ipsen Innovation $383.47 09/25/2025 Non-covered Recipient Entity
Neurology Offices South Florida
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184288682
Principal investigator 1 Ipsen Innovation $126.00 09/25/2025 Non-covered Recipient Entity
Neurology Offices South Florida
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184288684
Principal investigator 1 ABBVIE INC. $147.68 09/23/2025 Non-covered Recipient Entity
NEUROLOGY OFFICES OF S FL PLLC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202511920
Principal investigator 1 Eli Lilly and Company $2,900.00 08/25/2025 Non-covered Recipient Entity
NEUROLOGY OFFICES OF SOUTH FLORIDA, PLLC
ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF LY3372689 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1187884400
Principal investigator 1 ARGENX US, INC. $598.00 08/19/2025 Non-covered Recipient Entity
NEUROLOGY OFFICES OF SOUTH FLORIDA
A Long-Term, Single Arm, Open-Label, Multicenter, Phase 3 Study to Evaluate the Safety and Tolerability of Multiple Subcutaneous Injections of Efgartigimod PH20 SC in Patients With Generalized Myasthenia Gravis. No dispute reported 06/30/2026 1237154500
Principal investigator 1 ARGENX US, INC. $10,418.40 08/19/2025 Non-covered Recipient Entity
NEUROLOGY OFFICES OF SOUTH FLORIDA
A Long-Term, Single Arm, Open-Label, Multicenter, Phase 3 Study to Evaluate the Safety and Tolerability of Multiple Subcutaneous Injections of Efgartigimod PH20 SC in Patients With Generalized Myasthenia Gravis. No dispute reported 06/30/2026 1237154503
Principal investigator 1 ARGENX US, INC. $25,645.75 08/19/2025 Non-covered Recipient Entity
NEUROLOGY OFFICES OF SOUTH FLORIDA
A Long-Term, Single Arm, Open-Label, Multicenter, Phase 3 Study to Evaluate the Safety and Tolerability of Multiple Subcutaneous Injections of Efgartigimod PH20 SC in Patients With Generalized Myasthenia Gravis. No dispute reported 06/30/2026 1237154507
Principal investigator 1 ABBVIE INC. $1,854.00 08/18/2025 Non-covered Recipient Entity
NEUROLOGY OFFICES OF S FL PLLC
Study of Oral Atogepant When Added to OnabotulinumtoxinA (BOTOX) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Chronic Migraine No dispute reported 06/30/2026 1202505025
Principal investigator 1 ABBVIE INC. $2,925.45 07/02/2025 Non-covered Recipient Entity
NEUROLOGY OFFICES OF S FL PLLC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202496605
Principal investigator 1 ABBVIE INC. $2,925.45 06/03/2025 Non-covered Recipient Entity
NEUROLOGY OFFICES OF S FL PLLC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202488341
Principal investigator 1 ARGENX US, INC. $13,000.00 05/22/2025 Non-covered Recipient Entity
NEUROLOGY OFFICES OF SOUTH FLORIDA
A randomized, double-blinded, placebo-controlled, phase 3, parallel-group design study evaluating the efficacy and safety of efgartigimod PH20 SC administered by prefilled syringe in adult participants with ocular myasthenia gravis No dispute reported 06/30/2026 1237154519
Principal investigator 1 Celgene Corporation $11,571.13 05/21/2025 Non-covered Recipient Entity
Neurology Offices Of South Florida PLLC
A Multicenter, Longitudinal, Open-Label, Single-Arm Study Describing Cognitive Processing Speed Changes in Relapsing Multiple Sclerosis Subjects Treated with Ozanimod (RPC-1063) No dispute reported 06/30/2026 1222306211
Principal investigator 1 ARGENX US, INC. $2,200.00 05/08/2025 Non-covered Recipient Entity
NEUROLOGY OFFICES OF SOUTH FLORIDA
A randomized, double-blinded, placebo-controlled, phase 3, parallel group design study evaluating the efficacy and safety of efgartigimod IV in adult participants with acetylcholine receptor binding antibody (AChR-Ab) seronegative generalized myasthenia gravis (gMG). No dispute reported 06/30/2026 1237154481
Principal investigator 1 ABBVIE INC. $7,492.50 05/07/2025 Non-covered Recipient Entity
NEUROLOGY OFFICES OF S FL PLLC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202482715
Principal investigator 1 PFIZER INC. $3,465.30 04/24/2025 Non-covered Recipient Entity
NEUROLOGY OFFICES OF SOUTH FLORIDA PLLC
A PHASE 4 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RIMEGEPANT IN EPISODIC MIGRAINE PREVENTION WITH MULTIPLE DOSING REGIMENS No dispute reported 06/30/2026 1228763589
Principal investigator 1 ARGENX US, INC. $280.00 04/15/2025 Non-covered Recipient Entity
NEUROLOGY OFFICES OF SOUTH FLORIDA
A Long-Term, Single Arm, Open-Label, Multicenter, Phase 3 Study to Evaluate the Safety and Tolerability of Multiple Subcutaneous Injections of Efgartigimod PH20 SC in Patients With Generalized Myasthenia Gravis. No dispute reported 06/30/2026 1237154486
Principal investigator 1 ARGENX US, INC. $1,200.00 04/15/2025 Non-covered Recipient Entity
NEUROLOGY OFFICES OF SOUTH FLORIDA
A Long-Term, Single Arm, Open-Label, Multicenter, Phase 3 Study to Evaluate the Safety and Tolerability of Multiple Subcutaneous Injections of Efgartigimod PH20 SC in Patients With Generalized Myasthenia Gravis. No dispute reported 06/30/2026 1237154491
Principal investigator 1 ARGENX US, INC. $600.00 04/15/2025 Non-covered Recipient Entity
NEUROLOGY OFFICES OF SOUTH FLORIDA
A Long-Term, Single Arm, Open-Label, Multicenter, Phase 3 Study to Evaluate the Safety and Tolerability of Multiple Subcutaneous Injections of Efgartigimod PH20 SC in Patients With Generalized Myasthenia Gravis. No dispute reported 06/30/2026 1237154493
Principal investigator 1 ARGENX US, INC. $1,360.00 04/15/2025 Non-covered Recipient Entity
NEUROLOGY OFFICES OF SOUTH FLORIDA
A Long-Term, Single Arm, Open-Label, Multicenter, Phase 3 Study to Evaluate the Safety and Tolerability of Multiple Subcutaneous Injections of Efgartigimod PH20 SC in Patients With Generalized Myasthenia Gravis. No dispute reported 06/30/2026 1237154497
Principal investigator 1 ABBVIE INC. $3,678.75 04/03/2025 Non-covered Recipient Entity
NEUROLOGY OFFICES OF S FL PLLC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202473385
Principal investigator 1 ABBVIE INC. $3,775.00 03/10/2025 Non-covered Recipient Entity
NEUROLOGY OFFICES OF SOUTH FLORIDA PLLC
M21-307 - Study of BOTOX Injections in Prevention of Migraine in Adult Participants With Episodic Migraine No dispute reported 06/30/2026 1202462200
Principal investigator 1 ABBVIE INC. $4,050.00 03/07/2025 Non-covered Recipient Entity
NEUROLOGY OFFICES OF S FL PLLC
M23-714 - Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202461685
Principal investigator 1 ABBVIE INC. $300.00 02/27/2025 Non-covered Recipient Entity
NEUROLOGY OFFICES OF S FL PLLC
M22-418 - Study of Oral Atogepant When Added to OnabotulinumtoxinA (BOTOX) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Chronic Migraine No dispute reported 06/30/2026 1202454309
Principal investigator 1 ABBVIE INC. $1,008.00 02/27/2025 Non-covered Recipient Entity
NEUROLOGY OFFICES OF S FL PLLC
M22-418 - Study of Oral Atogepant When Added to OnabotulinumtoxinA (BOTOX) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Chronic Migraine No dispute reported 06/30/2026 1202454313
Principal investigator 1 ABBVIE INC. $2,925.00 02/27/2025 Non-covered Recipient Entity
NEUROLOGY OFFICES OF S FL PLLC
M22-418 - Study of Oral Atogepant When Added to OnabotulinumtoxinA (BOTOX) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Chronic Migraine No dispute reported 06/30/2026 1202454375
Principal investigator 1 ABBVIE INC. $4,726.35 02/06/2025 Non-covered Recipient Entity
NEUROLOGY OFFICES OF S FL PLLC
M23-714 - Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202447242
Principal investigator 1 ABBVIE INC. $1,000.00 02/05/2025 Non-covered Recipient Entity
NEUROLOGY OFFICES OF S FL PLLC
M22-418 - Study of Oral Atogepant When Added to OnabotulinumtoxinA (BOTOX) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Chronic Migraine No dispute reported 06/30/2026 1202444294
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $4,892.69 01/27/2025 Non-covered Recipient Entity
First Choice Neurology
A Randomized, Double-blind, Placebo-controlled, Global Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986446, an Anti-MTBR Tau Monoclonal Antibody, in Participants with Early Alzheimers Disease (TargetTau-1) No dispute reported 06/30/2026 1235997395
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $156,811.50 01/16/2025 Non-covered Recipient Entity
First Choice Neurology
A Randomized, Double-blind, Placebo-controlled, Global Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986446, an Anti-MTBR Tau Monoclonal Antibody, in Participants with Early Alzheimers Disease (TargetTau-1) No dispute reported 06/30/2026 1235997393
Principal investigator 1 Eli Lilly and Company $28.95 01/09/2025 Non-covered Recipient Entity
NEUROLOGY OFFICES OF SOUTH FLORIDA, PLLC
ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF LY3372689 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1187885906
Principal investigator 1 ABBVIE INC. $1,485.86 01/02/2025 Non-covered Recipient Entity
NEUROLOGY OFFICES OF S FL PLLC
M22-418 - Study of Oral Atogepant When Added to OnabotulinumtoxinA (BOTOX) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Chronic Migraine No dispute reported 06/30/2026 1202433949
Principal investigator 1 ABBVIE INC. $3,127.95 01/02/2025 Non-covered Recipient Entity
NEUROLOGY OFFICES OF S FL PLLC
M23-714 - Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202433953
Principal investigator 1 ARGENX US, INC. $87.69 01/02/2025 Non-covered Recipient Entity
NEUROLOGY OFFICES OF SOUTH FLORIDA
A randomized, double-blinded, placebo-controlled, phase 3, parallel group design study evaluating the efficacy and safety of efgartigimod IV in adult participants with acetylcholine receptor binding antibody (AChR-Ab) seronegative generalized myasthenia gravis (gMG). No dispute reported 06/30/2026 1237154515
Principal investigator 1 Novartis Pharmaceuticals Corporation $178,710.76 01/01/2025 Non-covered Recipient Entity
FIRST CHOICE NEUROLOGY
An Open label Single Arm Multi center Extension Study Evaluating Long term Safety Tolerability and Effectiveness of Ofatumumab in Subjects With Relapsing Multiple Sclerosis No dispute reported 06/30/2026 1190302137
Principal investigator 1 Novartis Pharmaceuticals Corporation $158,689.18 01/01/2025 Non-covered Recipient Entity
NEUROLOGY OFFICES OF SOUTH FLORIDA PLLC
A randomized, double-blind, placebo-controlled phase III study to evaluate the efficacy, safety, and tolerability of iptacopan in patients with generalized Myasthenia Gravis (gMG), followed by an open label extension phase No dispute reported 06/30/2026 1190308580